Abstract:Introduction Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. In the pivotal JULIET trial, 115 patients received tisagenlecleucel treatment; the best overall response rate (ORR) was 54% and complete response (CR) rate was 40%. At a median follow-up of 24 months, the median duration of response was not reached. Grade 3 or higher cytokine release syndrome (CRS) (UPenn scale) and neurotoxicity within the first 8 weeks after infusion occurred in 22.6% and 11.3%, respectively (Bachanova et. al. Hematol Oncol. Abstr 2019). CIBMTR CT Registry was developed to collect long-term safety and efficacy information on recipients of cellular immunotherapies and it is utilized for a post marketing study of tisagenlecleucel in the real-world setting. Methods Clinical data from the registry were analyzed for baseline information. Efficacy and safety data were collected from patients with a minimum of 3 months follow-up. CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported as per the consensus ASTCT criteria. Important manufacturing product characteristics of tisagenlecleucel were compared to clinical outcomes obtained by the CIBMTR CT registry. The association of number of cells administered, cell viability, potency, and transduction efficiency to overall response, CRS and ICANS grade was performed using descriptive summaries and univariate logistic regression analyses. Tisagenlecleucel cell product characterization by immunophenotyping was also compared to clinical outcomes in the CIBMTR Registry. Results Twenty-six centers contributed data for relapsed/refractory DLBCL patients through the CIBMTR CT registry as of May 31, 2019. Baseline information was available in 70 patients while outcomes ≥ 3 months post-infusion was available on 47 patients (Table 1). All patients received cells in the FDA approved range (0.6 to 6 x 108 CAR+ viable T cells) with a median of 1.7 x 108 (range 0.6-3.5 x 108). The median follow-up time for survivors was 5.8 months (0.9-8.9 months). The overall response rate (ORR) was 59.6% (28 of 47 patients) including 38.3% (18 patients) achieving a CR. The rate of grade 3 or higher CRS and ICANS was 4.3% and 4.3%, respectively. Tocilizumab and corticosteroids were administered in 40.9% and 9.1% among patients who had CRS. The median time to onset of CRS was 4.5 days and lasted for an average of 5 days. A total of 14 (29.8%) patients died after treatment, all due to disease progression and no deaths were attributed to toxicities from tisagenlecleucel. A secondary malignancy was reported in 1 patient (basal cell carcinoma) that was present prior to CAR-T cell infusion. Out of the products manufactured for these 47 patients, 21 were out-of-commercial specification (OOS) because of low cell viability (< 80%), however, efficacy and safety outcomes were similar to those with batches meeting viability specifications. None of the manufacturing characteristics analyzed (such as cell viability, potency or transduction efficiency) correlated with either efficacy (ORR) or safety (CRS or ICANS). Importantly, analysis of cell viability showed no association with best overall response (Table 2). Conclusions The CIBMTR CT registry represents real-world data for the treatment of adults with DLBCL and allows capture of long-term follow up (15 years). The efficacy and safety in the real world setting demonstrate similar efficacy and safety as compared with the pivotal JULIET trial. Cell product characteristics analyzed, including percentage of viable cells, do not correlate with response rates, CRS or ICANS. Updated results, including tisagenlecleucel cell product characterization, will be presented at the meeting. Disclosures Kamdar: Seattle Genetics: Speakers Bureau; Pharmacyclics: Consultancy; Celgene: Consultancy; AstraZeneca: Consultancy; University of Colorado: Employment. Perales:Medigene: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Kyte/Gilead: Research Funding; Miltenyi: Research Funding; Merck: Consultancy, Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; MolMed: Membership on an entity's Board of Directors or advisory committees; NexImmune: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bellicum: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Meyers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Nektar Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees. Nikiforow:Kite/Gilead: Honoraria; Novartis: Honoraria; NKarta: Honoraria. Jeschke:Novartis: Employment. Chawla:Novartis Pharma AG: Employment. Horowitz:Mesoblast: Other: Unrestricted educational and research grant, Research Funding; Gamida Cell: Other: Unrestricted educational and research grant, Research Funding; Chimerix: Other: Unrestricted educational and research grant; Janssen: Other: Unrestricted educational and research grant, Research Funding; Pharmacyclics: Other: Unrestricted educational and research grant; Daiichi Sankyo: Other: Unrestricted educational and research grant; Miltenyi Biotech: Other: Unrestricted educational and research grant, Research Funding; CSL Behring: Other: Unrestricted educational and research grant, Research Funding; Regeneron: Other: Unrestricted educational and research grant; Sanofi: Other: Unrestricted educational and research grant, Research Funding; Bristol-Myers Squibb: Other: Unrestricted educational and research grant, Research Funding; Seattle Genetics: Other: Unrestricted educational and research grant; Actinium: Other: Unrestricted educational and research grant; GlaxoSmithKline: Other: Unrestricted educational and research grant; Amgen: Other: Unrestricted educational and research grant; Kite Pharma/Gilead: Other: Unrestricted educational and research grant, Research Funding; Magenta: Consultancy, Other: Unrestricted educational and research grant; Shire: Other: Unrestricted educational and research grant; Oncoimmune: Other: Unrestricted educational and research grant. Bleickardt:Novartis: Employment. Pasquini:Pfizer: Other: Advisory Board; Amgen: Consultancy; Medigene: Consultancy; BMS: Research Funding; Kit Pharma: Research Funding; Novartis: Research Funding.

Abstract:The emerging individualized and living-cell-based genetic engineering chimeric antigen receptor T (CAR-T) therapy demonstrates great curative effects in some hematological tumor treatments, thus it is turning out to be a star immunotherapy method of the world.1Wagner D.L. Fritsche E. Pulsipher M.A. et al.Immunogenicity of CAR T cells in cancer therapy.Nat. Rev. Clin. Oncol. 2021; 18: 379-393Google Scholar Recently, the China National Medical Products Administration (NMPA) approved launching applications of two CAR-T cell cancer products, Axicabtagene Ciloleucel (FKC876) and Relmacabtagene Autoleucel (Carteyva), which marked the beginning of the of CAR-T cell therapy era in China (Figure 1). Axicabtagene Ciloleucel (FKC876) from Fosun Kite Biotech is the first product of its kind and is approved for the treatment of adult patients with relapsed or refractory large B cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse LBCL (DLBCL) not otherwise specified, primary mediastinal LBCL (PMBCL), high-grade B cell lymphoma, and DLBCL arising from follicular lymphoma. Relmacabtagene Autoleucel from JW Therapeutics is the second anti-CD19 autologous CAR-T cell therapy product approved by NMPA for treating adult patients with r/r LBCL after two or more lines of systemic therapy. It is worth noting that both of the approved CAR-T products are based on highly efficient international joint ventures' Hi-Tech cooperation.2Ning B. Zhao Y. To embrace open science more closely.The Innovation. 2020; 1: 100012Google Scholar Axicabtagene ciloleucel (FKC876), the CD19-targeting autologous CAR-T cell therapy product, was introduced from Kite Pharma's core product Yescarta in 2017, while Relmacabtagene Autoleucel (JWCAR029) was developed as a new therapy product based on Juno Therapeutics's Lisocabtagene Maraleucel (Liso-cel; JCAR017) research platform in 2016. After several years of localized research and development (R&D) and clinical trials, both CAR-T cell therapy products have been approved and supply new options and hopes to r/r LBCL patients that had previously exhausted all viable treatment options in China. As one of the world's leading CAR-T products, Yescarta has been shown to have good efficacy in a series of clinical studies. For example, the 2-year follow-up result of the ZUMA-1 study showed that in B cell lymphoma, the objective response rate (ORR) reached 83%, the complete response rate was 58%, and 39% of patients were in continuous remission.3Locke F.L. Ghobadi A. Jacobson C.A. et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol. 2019; 20: 31-42Google Scholar According to the Chinese bridging trial results, 79.2% of patients achieved a response after a single infusion of Axicabtagene Ciloleucel (FKC876), which demonstrated a similar efficacy and safety profile between FKC876 and Yescarta in the treatment of adult patients with r/r LBCL. The approval of Relmacabtagene Autoleucel is based on the results of a single-arm, multi-center, pivotal study. The corresponding RELIANCE study enrolled 59 patients with r/r LBCL who failed to respond to at least two lines of therapy. As of the June 17, 2020, data cut-off, the best overall response rate was 75.9%, with a best complete response rate of 51.7% in 58 evaluable patients and a 12-month overall survival (OS) rate of 76.8%.4Zhu J. Ying Z. Song Y. et al.Clinical response of cd19 car-t cells (relmacabtagene autoleucel, relma-cel) in adults with heavily-pre-treated relapsed/refractory (r/r) large b-cell lymphoma in China.Blood. 2020; 136: 39-40Google Scholar Accordingly, Relmacabtagene Autoleucel was the first CAR-T product approved as a category 1 biological product of China and the sixth approved CAR-T product globally. It is worth noting that the US Food and Drug Administration (FDA) also approved Lisocabtagene maraleucel for r/r LBCL in February of 2021, according to the clinical trial results of adult r/r LBCL patients after at least two lines of therapy. Of the 192 patients evaluable for a response, the overall response rate (ORR) per an independent review committee assessment was 73%, with a complete response (CR) rate of 54%. Over the last 4 years, FDA has approved five CAR-T products, including Kymriah from Novartis, Yescarta and Tecartus from Gilead, and Breyanzi and Abecma from Bristol Myers Squibb (Figure 1). The first four products are genetically CD19-targeting modified autologous T cell immunotherapies, while the last one is a B cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. These CAR-T cell therapies have been shown to be effective in treating different late-stage hematological tumors. Generally, based on a single administration, the genetically modified CAR-T cells recognize and kill tumor cells in a major histocompatibility complex (MHC)-independent fashion. CAR-T therapy significantly prolongs the survival time of patients and even cures some patients. Based on the great potential in hematological tumor treatments, there are abundant fierce CAR-T programs in R&D and clinical trials for cancer therapy that have been designed with unique advantages (e.g., dual-target, fully human CAR fragments, etc.). However, the mainstream use of CAR-T therapy is still in the second generation of CAR with 4-1BB as a costimulatory molecule, which enhances T cell proliferation and cytotoxicity through a costimulatory domain.5Larson R.C. Maus M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells.Nat. Rev. Cancer. 2021; 21: 145-161Google Scholar Recently, CAR-T therapy has also shown some breakthroughs in solid tumors other than blood tumors. At present, more than 14 solid tumor targets are in the clinical trials, including vascular endothelial growth factor (VEGF), prostate-specific membrane antigen (PSMA), epithelial cellular adhesion molecule (EpCAM), GPC3, and CLDN18.2. By selecting specific targets that are highly expressed in tumor tissues and optimizing the structure of CARs, a series of recent studies have shown the prospect of using CAR-T therapy in solid tumors, including melanoma, cervical cancer, lung cancer, mesothelioma, and esophageal cancer. More ongoing clinical trial information for CAR-T immunotherapy can be obtained through the following websites: US Clinical Trial (https://clinicaltrials.gov/) and Chinese Clinical Trial Register (ChiCTR; http://www.chictr.org.cn/enIndex.aspx). However, autologous CAR-T cell therapy needs individualized production and release, which lead to a long production cycle and extremely high costs. In order to reduce the long production cycle, scientists work in two ways: one is the development of the FasTCAR platform for shortening the CAR-T cell product preparation cycle, and the other is the allogeneic CAT technology, by which scientists try to generate off-the-shelf, universal CAR-T products using cells from allogeneic health donors through gene editing. To eliminate graft-versus-host disease (GVDH), TCR genes and HLA-I genes of T cells can be destroyed by gene-editing tools such as ZFN, TALEN, and CRISPR-Cas9.5Larson R.C. Maus M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells.Nat. Rev. Cancer. 2021; 21: 145-161Google Scholar Another problem related to the therapy is the possible adverse reactions, which may include lymphodepleting chemotherapy, adverse cardiovascular and pulmonary events, cytokine release syndrome, and neurotoxicity.5Larson R.C. Maus M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells.Nat. Rev. Cancer. 2021; 21: 145-161Google Scholar However, at this point, it is still too early to be able to recognize such adverse reactions for clinics. As a rising star immunotherapy therapeutic approach, CAR-T therapy has been receiving increasing attention. Accompanied by accelerated new technology and multi-disciplinary cooperation, the shortcomings will be gradually solved. Development of new CAR-T therapies will increase treatment options for patients with hematological or solid tumors. The authors declare no competing interests.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Low Dose of Human Scfv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma

Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (thiscart19a) with Enhanced Antitumor Potency for Treating B-ALL

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma

Abstract LB341: Clinical validation and mechanistic insights of ThisCART: A novel allogeneic platform enhancing CAR-T signaling via intracellular TCRαβ/CD3 retention

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Abstract 581: bbT369, a dual-targeted and CBLB gene-edited autologous CART product, demonstrates anti-lymphoma activity in preclinical mouse models

Eight-Day Point of Care CAR T-Cell Manufacturing on Clinimacs Prodigy from Healthy Donors As a Proof-of-Concept Study

Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Abstract 6325: Lineage tracing defines responding CAR T cells in patients with B cell malignancies

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Abstract 2835: Chimeric antigen receptor (CAR) T-cell generation for therapeutic testing in the disseminated NALM6 human B-cell acute lymphoblastic leukemia mouse model

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

China Enters CAR-T Cell Therapy Era